Research synthesis only; not medical advice. Route selection, device choice, and administration technique are product-specific decisions governed by the approved labeling. This page explains the pharmacokinetic and pharmaceutical principles; it does not provide administration instructions.
Routes of administration for peptide products
Peptides are generally not orally bioavailable due to proteolytic degradation in the gastrointestinal tract and poor permeability across the intestinal epithelium (molecular mass typically >500 Da, log P <0, polar surface area >140 Ų). Parenteral routes are therefore standard.
Subcutaneous (SC)
Most common route for peptide products (e.g., insulin, GLP-1 receptor agonists, teriparatide)
Absorption occurs via capillaries and lymphatic vessels
Bioavailability is typically 60--100%, limited primarily by local proteolysis and, for larger peptides (>16 kDa), lymphatic uptake
Tolerable volume and absorption are product-, formulation-, device-, site-, and patient-specific; they cannot be inferred from peptide mass
Absorption rate depends on:
Labeled administration site and local blood flow
Blood flow (increased by exercise, heat; decreased by cold, vasoconstrictors)
Molecular size (small peptides enter capillaries; larger peptides require lymphatic transport, which is slower)
Formulation factors (viscosity, pH, presence of absorption enhancers)
Intramuscular (IM)
Used for some depot formulations; acceptable volume and technique are product-, site-, patient-, and professional-protocol-specific
Absorption is generally faster than SC due to richer blood supply
Risk of injection into a blood vessel (intravascular) or nerve
Rate depends on the same factors as SC, with muscle blood flow being the primary determinant
Intravenous (IV)
Complete (100%) bioavailability; immediate onset
Used when rapid effect is required or when SC/IM bioavailability is insufficient
Requires careful rate control (bolus vs. infusion) and formulation compatibility with blood
Higher risk of adverse events due to rapid systemic exposure
Intranasal
Bypasses first-pass metabolism; rapid absorption via nasal mucosa
Limited to small, potent peptides (e.g., desmopressin, calcitonin)
Bioavailability typically 1--10% due to mucociliary clearance, enzymatic barrier, and limited permeability
Absorption enhancers (e.g., cyclodextrins, surfactants) sometimes included in approved products
Transdermal
Passive transdermal delivery of peptides is generally infeasible due to molecular size and hydrophilicity
Active methods (iontophoresis, microneedle arrays, sonophoresis, thermal poration) are investigational; few peptide products available via these routes
No approved transdermal peptide system for hypoparathyroidism is currently identified; the approved product (Yorvipath) is administered subcutaneously
Pulmonary
Large surface area (~100 m²) in alveoli; thin absorption barrier (0.1--0.2 µm)
Investigational for peptide systemic delivery (e.g., inhaled insulin — Exubera, Afrezza — withdrawn or limited in market)
Challenges: enzyme barrier, mucociliary clearance, phagocytosis by alveolar macrophages, device reproducibility
Depot and controlled-release formulations
Strategies to extend peptide exposure and reduce injection frequency include:
Polymeric microspheres: Peptide encapsulated in biodegradable poly(lactic-co-glycolic acid) (PLGA) microspheres; release governed by diffusion and polymer erosion (e.g., leuprolide acetate depot)
In situ depot-forming systems: Polymer solution injected subcutaneously; upon contact with aqueous tissue fluid, solvent diffuses and polymer precipitates, entrapping peptide (e.g., Eligard)
Lipid-based formulations: Liposomes, solid lipid nanoparticles, lipid microspheres
Covalent modification: PEGylation (attachment of polyethylene glycol chains) increases hydrodynamic size, reduces renal clearance, and can extend half-life 10--100-fold (e.g., pegvisomant, PEG-filgrastim)
Fusion proteins: Fusion to an Fc domain (e.g., dulaglutide) or albumin-binding domain exploits neonatal Fc receptor (FcRn) recycling to extend half-life from hours to days or weeks
Devices
| Device type | Examples of peptide products | Key attributes |
|---|---|---|
| Pre-filled syringe | Enoxaparin, teriparatide | Single dose; ready-to-use; fixed needle or luer-lock; dose accuracy ±5--10% |
| Injection pen | Insulin, GLP-1 agonists, somatropin | Multi-dose; dose selector with audible clicks; replaceable needle; preservative-containing formulation |
| Auto-injector | Epinephrine, certain GLP-1 products | Concealed needle; spring-actuated; single fixed dose; designed for patient self-administration |
| Infusion pump | Insulin (CSII), pramlintide, certain cancer peptides | Continuous or programmable delivery; reservoir refill; requires battery and tubing |
| Implant | Leuprolide acetate (Viadur, no longer marketed), histrelin acetate | Long-term release (months to years); requires surgical insertion and removal |
| Dry-powder inhaler | Inhaled insulin (Afrezza) | Breath-actuated; peptide in powder form; pulmonary delivery |
| Needle-free injector | Various (some Somatropin products) | Liquid jet through skin; may reduce needle phobia; risk of bruising and variable absorption |
Route-dependent pharmacokinetics
Key PK differences by route:
| Parameter | SC | IM | IV | Intranasal |
|---|---|---|---|---|
| Typical Tmax | 30--120 min | 15--60 min | 0 (immediate) | 10--30 min |
| Bioavailability (F) | 50--100% | 50--100% | 100% | 1--10% |
| Typical half-life change | Unchanged from IV | Unchanged from IV | Reference | Often shorter (enzymatic degradation) |
| Duration | Short unless formulated for extended release | Short unless formulated for extended release | Short unless formulated for extended release | Short |
Sources
Porter CJH, Charman SA, Charman WN. Lymphatic transport of peptides and proteins following subcutaneous administration. J Pharm Sci. 2001;90(7):819--835. https://doi.org/10.1002/jps.1040
Zijlstra E, Jahnke J, Fischer A, Kapitza C, Forst T. Impact of injection site on absorption and pharmacokinetics of rapid-acting insulin. J Diabetes Sci Technol. 2013;7(4):1007--1013. https://doi.org/10.1177/193229681300700425
FDA. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products — General Considerations. 2003. https://www.fda.gov/media/71854/download
Illum L. Nasal drug delivery — possibilities, problems and solutions. J Control Release. 2003;87(1--3):187--198. https://doi.org/10.1016/s0168-3659(02)00363-2
US Pharmacopeia. USP General Chapter
<1151>Pharmaceutical Dosage Forms. USP–NF. Rockville, MD: United States Pharmacopeia; 2026.Park K, Kwon IC, Yeo Y, et al. Controlled drug delivery systems: current status and future directions. Mol Pharm. 2021;18(3):819--834. https://doi.org/10.1021/acs.molpharmaceut.0c00968
Dubowchik GM, Deshpande M, Bhatt V, et al. PEGylated peptides. Bioorg Med Chem Lett. 1999;9(17):2539--2544.